Navigation Links
Regeneron Announces Appointment of Joseph J. LaRosa as Senior Vice President, General Counsel and Secretary
Date:9/6/2011

TARRYTOWN, N.Y., Sept. 6, 2011 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) today announced that Joseph J. LaRosa has been appointed Senior Vice President, General Counsel and Secretary.  Mr. LaRosa will be responsible for overseeing all of the Company's legal affairs, including general corporate legal matters, intellectual property and corporate compliance, and will report to Leonard S. Schleifer, M.D., Ph.D., president and chief executive officer.

"We are extremely pleased to have recruited a seasoned corporate attorney with deep senior-level pharmaceutical experience to lead this important function," said Dr. Schleifer.  "Joe's track record managing a variety of key legal functions at Schering-Plough and Nycomed will be directly relevant as Regeneron, which now employs more than 1,600 people, continues to build its product portfolio and the capabilities of a fully integrated pharmaceutical company."

Previously, Mr. LaRosa held a number of senior legal positions at Schering-Plough Corporation, where he was a corporate officer and served most recently as Vice President, Legal Affairs, and a member of the Operations Management Team.  He also served as Vice President, Global Compliance and Legal Affairs at Avon Products, Inc.  Most recently Mr. LaRosa was Senior Vice President, General Counsel and Secretary at Nycomed US Inc.

"I am excited to join the Regeneron senior management team at a time when the company is emerging as one of the best-positioned biotechnology companies," said Mr. LaRosa, who holds undergraduate and J.D. degrees from New York University.  "Regeneron is known for outstanding science and innovative collaborations with leading pharmaceutical companies, and in recent years it has also demonstrated its abilities in clinical development, manufacturing, and commercialization of new biotechnology-based drugs."

About Regeneron Pharmaceuticals Regeneron is a fully integrated biopharmaceutical company that discovers, develops, manufacturers, and commercializes medicines for the treatment of serious medical conditions. In addition to ARCALYST® (rilonacept) Injection for Subcutaneous Use, which is approved for the treatment of a rare inflammatory condition, Regeneron has completed Phase 3 clinical trials of rilonacept for a new indication and of product candidates EYLEA™ (aflibercept injection; VEGF Trap Eye) in diseases of the eye and ZALTRAP® (aflibercept) (VEGF Trap) in colorectal cancer.  EYLEA is currently under review with U.S. and European regulatory authorities.  Additional therapeutic candidates developed from proprietary Regeneron technologies for creating fully human monoclonal antibodies are in earlier stage development programs in rheumatoid arthritis, pain, cholesterol reduction, allergic and immune conditions, and cancer.  Additional information about Regeneron and recent news releases are available on www.regeneron.com.Contact Information:Michael Aberman, M.D.

Peter DworkinInvestor Relations

Corporate Communications914.345.7799

914.345.7640michael.aberman@regeneron.com

peter.dworkin@regeneron.com
'/>"/>

SOURCE Regeneron Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Regeneron Announces Review of Biologics License Application for EYLEAâ„¢ (aflibercept injection) Extended by Three Months by FDA
2. Regeneron Announces Presentation at the 29th Annual J.P. Morgan Healthcare Conference
3. Regeneron Announces Presentation at the 2010 Deutsche Bank BioFest
4. Regenerons Rilonacept Granted European Marketing Authorization for Treatment of Cryopyrin-Associated Periodic Syndromes (CAPS)
5. Regeneron Pharmaceuticals and BioMed Realty Trust Host Ribbon-Cutting Ceremony at the Landmark at Eastview
6. BioMed Realty Trust Expands Landmark Leases With Regeneron Pharmaceuticals
7. Genprex Announces New Branding
8. BioMed Realty Announces Repurchase at Option of Holders and Redemption of 4.50% Exchangeable Senior Notes Due 2026
9. BioInformatics LLC Announces the Life Science Industry Awards on November 15, 2011 in Washington, DC
10. Jeunesse Global Announces New Medical Advisory Board Member and Admittance Into the Direct Selling Association (DSA).
11. BD Biosciences Announces Winners of Research Grant Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/9/2016)... BERG, a biopharmaceutical company uncovering health ... announced the appointment of Jason Haddock ... Haddock brings to BERG over 20 years of ... senior financial functions at pharmaceutical companies, as well ... Niven R. Narain , BERG,s ...
(Date:2/8/2016)... , Feb. 8, 2016  CytRx Corporation (NASDAQ: ... company specializing in oncology, today announced that it ... agreement with Hercules Technology Growth Capital, Inc. and ... million in financing. --> ... $25 million of financing under the loan and ...
(Date:2/8/2016)... Feb. 8, 2016  BioElectronics Corporation (OTC Pink: ... announced today that it is responding to a ... the Securities and Exchange Commission posted on the ... Chairman of the Board of BioElectronics Corporation and ... Administration at The Fuqua School of Business, Duke ...
(Date:2/8/2016)... Conn. , Feb. 8, 2016  NanoViricides, Inc. (NYSE MKT: ... its CEO, Eugene Seymour , MD, MPH, will present information ... at the Waldorf-Astoria Hotel in New York City ... will be in the Windsor Room at 5:30PM EST. Registered attendees ... New York City . --> ...
Breaking Biology Technology:
(Date:2/9/2016)... 2016 Vigilant Solutions announces today that an agency ... develop a lead in a difficult homicide case. The agency ... locate the suspect vehicle. Due to the ongoing investigation, the ... omitted at the agency,s request. --> ... victim was found deceased at an intersection here in the ...
(Date:2/3/2016)... GOTHENBURG, Sweden , February 4, 2016 ... Revenues amounted to SEK 1,351.5 M (105.0), up 1,187% compared with fourth ... Operating profit amounted to SEK 517.6 M (loss: 30.0). Earnings ... from operating activities was SEK 537.4 M (neg: 74.7). , ... , Revenues amounted to SEK 2,900.5 M (233.6), up 1,142% ...
(Date:2/2/2016)... NEW YORK , Feb. 2, 2016 ... healthcare facilities are primarily focused on medical ... that measure point-of-care parameters. Wearable devices that ... a user,s freedom of movement are being ... sensors for human biomedical signal acquisition coupled ...
Breaking Biology News(10 mins):